Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 61Carcinoma, Renal Cell 39Neoplasm Metastasis 38Neoplasms 24Kidney Neoplasms 20Neuroendocrine Tumors 19Recurrence 16Prostatic Neoplasms 15Head and Neck Neoplasms 13Tuberous Sclerosis 12Triple Negative Breast Neoplasms 12Lymphoma, Mantle-Cell 11Hodgkin Disease 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Colorectal Neoplasms 10Waldenstrom Macroglobulinemia 9Stomach Neoplasms 9Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Glioblastoma 9Brain Neoplasms 9Sarcoma 8Pancreatic Neoplasms 8Melanoma 8Lymphoma, Follicular 8Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8

Interventions

Propranolol 9Timolol 5Prednisolone 5Adrenergic beta-Antagonists 3Steroids 2Solutions 2Saline Solution 2Prednisone 2Methylprednisolone 2Adrenal Cortex Hormones 2prednisolone phosphate 1Vincristine 1Urine Specimen Collection 1Tomography, Optical Coherence 1Therapeutics 1Sodium Chloride 1Sirolimus 1Population Groups 1Ointments 1Observation 1Nadolol 1Mupirocin 1Lasers, Semiconductor 1Lasers, Dye 1Imiquimod 1High-Energy Shock Waves 1Hepatectomy 1Gels 1Everolimus 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangioma × Everolimus × Clear all
NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Yonsei University

Phase 2 Not yet recruiting
67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡